DMN Stock Overview
Develops precision medicine therapies for the treatment of autoimmune diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Diamyd Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.99 |
| 52 Week High | SEK 1.78 |
| 52 Week Low | SEK 0.55 |
| Beta | 2.14 |
| 11 Month Change | -10.99% |
| 3 Month Change | -31.58% |
| 1 Year Change | 65.77% |
| 33 Year Change | -37.23% |
| 5 Year Change | 41.75% |
| Change since IPO | 37.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -0.7% | 0.2% |
| 1Y | 65.8% | -17.2% | 8.5% |
Return vs Industry: DMN exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: DMN exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| DMN volatility | |
|---|---|
| DMN Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: DMN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DMN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 25 | Ulf Hannelius | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
| DMN fundamental statistics | |
|---|---|
| Market cap | €114.05m |
| Earnings (TTM) | -€13.20m |
| Revenue (TTM) | €11.30k |
Over9,999x
P/S Ratio-8.6x
P/E RatioIs DMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMN income statement (TTM) | |
|---|---|
| Revenue | SEK 130.00k |
| Cost of Revenue | SEK 3.71m |
| Gross Profit | -SEK 3.58m |
| Other Expenses | SEK 148.27m |
| Earnings | -SEK 151.85m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 29, 2025
| Earnings per share (EPS) | -1.46 |
| Gross Margin | -2,753.85% |
| Net Profit Margin | -116,807.69% |
| Debt/Equity Ratio | 0% |
How did DMN perform over the long term?
See historical performance and comparison